ReviewCancer pathogenesis and therapy2026
Mortality risk in patients with urological malignancies and human immunodeficiency virus (HIV) coinfection: A systematic review and meta-analysis of cohort studies.
Review in Cancer pathogenesis and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The extended survival of people living with human immunodeficiency virus (HIV) (PLWH) has shifted cancer burdens toward urological malignancies. PLWH exhibit unique clinical patterns, including a younger age at diagnosis for renal cell carcinoma and more advanced stage at presentation of prostate and bladder cancers, which are compounded by inequities in health care access and HIV-specific mechanisms such as chronic immunosuppression. Methods: A systematic search was conducted across five databases (Web of Science, PubMed, Cochrane Library, Embase, and Scopus) up to 1 July, 2025. Random-effects models were used to pool hazard ratios (HRs) and adjusted hazard ratios (aHRs). Publication bias was assessed using Egger's test, and sensitivity analyses were performed. Results: Nine studies with 6,615,444 participants were included. The risk factors for mortality such as kidney cancer (aHR = 1.74; 95% confidence interval [CI]: 1.11-2.75), prostate cancer (HR = 1.77; 95% CI: 1.60-1.96; aHR = 2.27; 95% CI: 1.77-2.90), and bladder cancer (aHR = 4.29; 95% CI: 1.08-17.03) were significantly higher for PLWH. The pooled unadjusted HR for kidney cancer was 1.66 (95% CI: 0.83-3.30), which did not reach statistical significance. Subgroup analyses for prostate cancer confirmed a consistent increase in mortality risk across different mortality types and follow-up durations. Conclusion: HIV infection is significantly associated with increased mortality among patients with prostate cancer. For kidney cancer, limited data suggest an adverse prognostic role of HIV. For bladder cancer, the evidence remains preliminary but highlights the urgent need for dedicated investigations. These findings highlight the need to integrate urological cancer screening and tailored management into long-term HIV care. Future multicenter studies will be essential to strengthen the evidence, particularly for kidney and bladder cancers, and to clarify the roles of HIV-specific factors, tumor biology, and social determinants of health in optimizing precision medicine for this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.